0512-67998889(Suzhou)
18051093220(Shenzhen)
Leading Innovation, RocRock Biotech's Outstanding Achievements in the Field of Biomedicine Highly Recognized by the Industry
On June 14-15, 2024, in the just announced 2024 IBIEXPO Annual Top 50 Most Innovative Companies in the Biopharmaceutical Industry, RocRock Biotech Co., Ltd. was honored as the most innovative company for its breakthrough progress in CAR-M cell therapy technology. This accolade signifies RocRock's exceptional scientific research capabilities and achievements in the field of innovative drug development in biomedicine.
The conference was convened by Yimaike in partnership with Nanjing Biopharmaceutical Valley at the Nanjing Yangtze River International Convention Center. It brought together over 200 authoritative Principal Investigators (PIs) and industry leaders, featuring more than 20 specialized forums to comprehensively and deeply discuss hot topics and cutting-edge scientific research achievements in the current field of biopharmaceutical innovation. The event was packed with attendees, who together witnessed the brilliant achievements of the biopharmaceutical innovation industry and collaborated to create new milestones for the future. This conference was not only a comprehensive showcase of the current state of biopharmaceutical innovation but also a forward-looking discussion and outlook for future development.
RocRock Biotech, as a high-tech enterprise dedicated to the research and development of macrophage drugs, has been committed to providing safer and more effective treatment options for patients with solid tumors since its establishment in 2021. Driven by innovation and with the vision of making affordable anti-cancer drugs for the general public, the company continuously advances biotechnological developments to improve patients' quality of life and extend survival periods.
As a pioneer in the field of CAR-M cell therapy in China, RocRock Biotech actively constructs a comprehensive industrial chain system centered around macrophage research. The company focuses not only on the development of anti-tumor drugs modified with chimeric antigen receptors but also promotes the broad application of macrophage drugs in chronic diseases and aging. Through continuous innovation and optimization, RocRock Biotech is striving to transform cutting-edge macrophage research into practical clinical applications, contributing more to the cause of human health.
At the Sixth Biannual Cancer Immunocell Therapy Technology Seminar, a sub-forum of the Biomedical Innovation Drug Industry Conference, RocRock Biotech shared and discussed cutting-edge information with industry veterans and was awarded one of the Top 50 Most Innovative Companies in the industry. This honor not only affirms RocRock Biotech's current R&D capabilities but also greatly encourages its potential for future development in the field of biomedicine. RocRock Biotech will maintain in-depth exploration and continuous innovation in the field of CAR-M therapy for solid tumors, striving for more breakthroughs, continuously demonstrating its unique R&D appeal, and continuing to contribute more and better efforts to the cause of human health, adding bricks and mortar to the well-being of global health.
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)